Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

GFH375

Phase 3Small molecule

GGenfleet Therapeutics (Shanghai) Inc.

GFH375 is one of 45 small molecule programs targeting KRAS G12D. It is currently in Phase 3.

3

Indications

6

Total Trials

5

Active Trials

44

Competitors

Pipeline

Status by Indication[3][1]

Indication

KRAS G12DRecruiting

Metastatic Pancreatic CancerRecruiting

Patients With Advanced Solid TumorsRecruiting

KRAS G12DPhase 3

Recruiting

Metastatic Pancreatic CancerPhase 3

Recruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Keytruda

Eloxatin

Tecentriq

Camptosar

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Lazcluze

Johnson & Johnson

Erbitux

Tuoyi

CCoherus Oncology, Inc.

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Metastatic Pancreatic Cancer

NCT07262567

Q4 2028

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT06500676

Q3 2029

Phase 2Recruiting

Pancreatic Cancer

NCT07784374

Q2 2030

Phase 3Not yet recruiting

Colorectal Cancer

NCT07913360

Clinical

Trials by Indication[1]

Pancreatic Cancer2 trials

A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer

Withdrawn·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT07026916

A Phase II, Multicenter, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of GFH375 in Combination With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 2·NCT07784374·120 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 1/2·NCT06500676·407 enrolled

Colorectal Cancer1 trial

A Multicenter, Open-label, Randomized Controlled Phase III Study Evaluating the Efficacy and Safety/Tolerability of GFH375 in Combination With Cetuximab Versus Investigator's Choice of Treatment in Patients With KRAS G12D Mutant Metastatic Colorectal Cancer Refractory to Oxaliplatin, Fluoropyrimidines, and Irinotecan

Not yet recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07913360·368 enrolled

Metastatic Pancreatic Cancer1 trial

A Multicenter, Open-Label, Randomized Controlled Phase III Study to Compare the Efficacy and Safety/Tolerability of GFH375 Monotherapy Versus Investigator's Choice of Chemotherapy in Patients With Previously Treated KRAS G12D-Mutant Metastatic Pancreatic Cancer

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07262567·320 enrolled

KRAS G12D1 trial

A Phase III, Randomized, Open-Label, Multicenter Study to Evaluate GFH375 Versus Docetaxel in Participants With Locally Advanced and Unresectable or Metastatic Non-Small Cell Lung Cancer With KRAS G12D Mutation Failed Prior Standard Therapy

Recruiting·GGenfleet Therapeutics (Shanghai) Inc.·Phase 3·NCT07668752·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for GFH375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GFH375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GFH375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genfleet Therapeutics (Shanghai) Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGenfleet Therapeutics (Shanghai) Inc.

Related News